Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
1174
mi
from 43215
Golden, CO
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
1174
mi
from 43215
Golden, CO
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
943
mi
from 43215
Boynton Beach, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
943
mi
from 43215
Boynton Beach, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
922
mi
from 43215
Fort Myers, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
922
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
993
mi
from 43215
Miami, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
970
mi
from 43215
Plantation, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
970
mi
from 43215
Plantation, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
874
mi
from 43215
Sarasota, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
874
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
896
mi
from 43215
Stuart, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
896
mi
from 43215
Stuart, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
830
mi
from 43215
Winter Haven, FL
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
830
mi
from 43215
Winter Haven, FL
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
430
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
189
mi
from 43215
New Albany, IN
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
189
mi
from 43215
New Albany, IN
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
623
mi
from 43215
Leawood, KA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
623
mi
from 43215
Leawood, KA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
784
mi
from 43215
Wichita, KA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
841
mi
from 43215
Eunice, LA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
841
mi
from 43215
Eunice, LA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
643
mi
from 43215
Boston, MA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
248
mi
from 43215
Grand Rapids, MI
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
398
mi
from 43215
Florissant, MO
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
398
mi
from 43215
Florissant, MO
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
477
mi
from 43215
Teaneck, NJ
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
477
mi
from 43215
Teaneck, NJ
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
302
mi
from 43215
Asheville, NC
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
302
mi
from 43215
Asheville, NC
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
168
mi
from 43215
West Mifflin, PA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
168
mi
from 43215
West Mifflin, PA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
358
mi
from 43215
Greenville, SC
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
358
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
358
mi
from 43215
Greenville, SC
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
358
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
1071
mi
from 43215
Rapid City, SD
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
1071
mi
from 43215
Rapid City, SD
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
1291
mi
from 43215
McAllen, TX
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
1291
mi
from 43215
McAllen, TX
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
1009
mi
from 43215
Temple, TX
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
1009
mi
from 43215
Temple, TX
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
974
mi
from 43215
The Woodlands, TX
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
974
mi
from 43215
The Woodlands, TX
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
Clinical Research Facility
278
mi
from 43215
Charlottesville, VA
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
Clinical Research Facility
278
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated:  11/19/2015
9463
mi
from 43215
Strathfield,
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Status: Enrolling
Updated: 11/19/2015
9463
mi
from 43215
Strathfield,
Click here to add this to my saved trials
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Status: Enrolling
Updated:  11/30/2015
Juels Stein Eye Institute
1982
mi
from 43215
Los Angeles, CA
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Status: Enrolling
Updated: 11/30/2015
Juels Stein Eye Institute
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Clinical Study of the Optic Disc Parameters
Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue
Status: Enrolling
Updated:  11/30/2015
Western University of Health Sciences
1946
mi
from 43215
Pomona, CA
Clinical Study of the Optic Disc Parameters
Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue
Status: Enrolling
Updated: 11/30/2015
Western University of Health Sciences
1946
mi
from 43215
Pomona, CA
Click here to add this to my saved trials
Clinical Study of the Optic Disc Parameters
Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue
Status: Enrolling
Updated:  11/30/2015
SUNY College of Optometry
478
mi
from 43215
New York, NY
Clinical Study of the Optic Disc Parameters
Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue
Status: Enrolling
Updated: 11/30/2015
SUNY College of Optometry
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Status: Enrolling
Updated:  12/1/2015
University of New England
691
mi
from 43215
Biddeford, ME
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Status: Enrolling
Updated: 12/1/2015
University of New England
691
mi
from 43215
Biddeford, ME
Click here to add this to my saved trials
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Status: Enrolling
Updated:  12/1/2015
University of Maine
805
mi
from 43215
Orono, ME
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Status: Enrolling
Updated: 12/1/2015
University of Maine
805
mi
from 43215
Orono, ME
Click here to add this to my saved trials
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Status: Enrolling
Updated:  12/1/2015
The Iris Network
703
mi
from 43215
Portland, ME
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Balancing Act: Impact on Falls in Older Adults With Vision Impairment
Status: Enrolling
Updated: 12/1/2015
The Iris Network
703
mi
from 43215
Portland, ME
Click here to add this to my saved trials
Dose-Ranging Study of the Bimatoprost Ocular Insert
A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  12/1/2015
Sall Medical Research Center
1968
mi
from 43215
Artesia, CA
Dose-Ranging Study of the Bimatoprost Ocular Insert
A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 12/1/2015
Sall Medical Research Center
1968
mi
from 43215
Artesia, CA
Click here to add this to my saved trials
The Post-Vitrectomy Lenstatin™ Study
The Post-Vitrectomy Lenstatin Study: A Prospective Randomized Double Blind Human Clinical Trial Testing the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy
Status: Enrolling
Updated:  12/3/2015
Scott W. Tunis MD FACS
488
mi
from 43215
Wilmington, NC
The Post-Vitrectomy Lenstatin™ Study
The Post-Vitrectomy Lenstatin Study: A Prospective Randomized Double Blind Human Clinical Trial Testing the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy
Status: Enrolling
Updated: 12/3/2015
Scott W. Tunis MD FACS
488
mi
from 43215
Wilmington, NC
Click here to add this to my saved trials
Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP)
The Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure
Status: Enrolling
Updated:  12/4/2015
Minimally Invasive Surgeons of Texas
997
mi
from 43215
Bellaire, TX
Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP)
The Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure
Status: Enrolling
Updated: 12/4/2015
Minimally Invasive Surgeons of Texas
997
mi
from 43215
Bellaire, TX
Click here to add this to my saved trials
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism
Status: Enrolling
Updated:  12/4/2015
University of Virginia Driving Safety Lab
278
mi
from 43215
Charlottesville, VA
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism
Evaluating and Improving Functional Driving Vision of Patients With Astigmatism
Status: Enrolling
Updated: 12/4/2015
University of Virginia Driving Safety Lab
278
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
iDropper Usability in Glaucoma
Improving Ophthalmic Medication Adherence
Status: Enrolling
Updated:  12/6/2015
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
iDropper Usability in Glaucoma
Improving Ophthalmic Medication Adherence
Status: Enrolling
Updated: 12/6/2015
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery
Status: Enrolling
Updated:  12/7/2015
Lyndon B. Johnson General Hospital
988
mi
from 43215
Houston, TX
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery
Status: Enrolling
Updated: 12/7/2015
Lyndon B. Johnson General Hospital
988
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery
Status: Enrolling
Updated:  12/7/2015
Robert Cizik Eye Clinic
995
mi
from 43215
Houston, TX
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery
Status: Enrolling
Updated: 12/7/2015
Robert Cizik Eye Clinic
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics
Prospective, Randomized, Observational Cohort Study of Antibiotic Resistance After Repeated Application of Topical Antibiotics
Status: Enrolling
Updated:  12/7/2015
Vanderbilt Eye Institute
331
mi
from 43215
Nashville, TN
Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics
Prospective, Randomized, Observational Cohort Study of Antibiotic Resistance After Repeated Application of Topical Antibiotics
Status: Enrolling
Updated: 12/7/2015
Vanderbilt Eye Institute
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria
Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study
Status: Enrolling
Updated:  12/8/2015
Vision Specialists of Birmingham
178
mi
from 43215
Birmingham, MI
Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria
Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study
Status: Enrolling
Updated: 12/8/2015
Vision Specialists of Birmingham
178
mi
from 43215
Birmingham, MI
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
1979
mi
from 43215
Beverly Hills, CA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
1979
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
432
mi
from 43215
Atlanta, GA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
188
mi
from 43215
Louisville, KY
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis
345
mi
from 43215
Baltimore, MD
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials